JW Holdings acquires world’s first Japanese approval for early pancreatic cancer testing technology

Published: 2018-06-11 16:27:00
Updated: 2018-06-11 17:15:49

JW Holdings was certified in novelty for its early pancreatic cancer diagnostic technology from the Japan Patent Office.

JW Holdings(CEO Sung-Kwon Han) announced on the 7th that the company has acquired Japanese approval of its original technology for the world’s first ‘multi-biomarker/test kits...


- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.

Original Korean

Most Read News

Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.